Cargando…
Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer
The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase th...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262579/ https://www.ncbi.nlm.nih.gov/pubmed/22295231 http://dx.doi.org/10.4061/2011/710292 |
_version_ | 1782221746389123072 |
---|---|
author | Soriano, Jorge L. Batista, Noyde Santiesteban, Eduardo Lima, Mayté González, Joaquín García, Robin Zarza, Yohanka López, María V. Rodríguez, Myriam Loys, Jorge L. Montejo, Narciso Aguirre, Frank Macías, Amparo Vázquez, Ana M. |
author_facet | Soriano, Jorge L. Batista, Noyde Santiesteban, Eduardo Lima, Mayté González, Joaquín García, Robin Zarza, Yohanka López, María V. Rodríguez, Myriam Loys, Jorge L. Montejo, Narciso Aguirre, Frank Macías, Amparo Vázquez, Ana M. |
author_sort | Soriano, Jorge L. |
collection | PubMed |
description | The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally daily and 2.5 mg of methotrexate orally bi-daily), in combination with five bi-weekly subcutaneous injections of 1 mg of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was 18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild. Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration. |
format | Online Article Text |
id | pubmed-3262579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-32625792012-01-31 Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer Soriano, Jorge L. Batista, Noyde Santiesteban, Eduardo Lima, Mayté González, Joaquín García, Robin Zarza, Yohanka López, María V. Rodríguez, Myriam Loys, Jorge L. Montejo, Narciso Aguirre, Frank Macías, Amparo Vázquez, Ana M. Int J Breast Cancer Clinical Study The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally daily and 2.5 mg of methotrexate orally bi-daily), in combination with five bi-weekly subcutaneous injections of 1 mg of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was 18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild. Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration. SAGE-Hindawi Access to Research 2011 2011-07-14 /pmc/articles/PMC3262579/ /pubmed/22295231 http://dx.doi.org/10.4061/2011/710292 Text en Copyright © 2011 Jorge L. Soriano et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Soriano, Jorge L. Batista, Noyde Santiesteban, Eduardo Lima, Mayté González, Joaquín García, Robin Zarza, Yohanka López, María V. Rodríguez, Myriam Loys, Jorge L. Montejo, Narciso Aguirre, Frank Macías, Amparo Vázquez, Ana M. Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
title | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
title_full | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
title_fullStr | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
title_full_unstemmed | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
title_short | Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer |
title_sort | metronomic cyclophosphamide and methotrexate chemotherapy combined with 1e10 anti-idiotype vaccine in metastatic breast cancer |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262579/ https://www.ncbi.nlm.nih.gov/pubmed/22295231 http://dx.doi.org/10.4061/2011/710292 |
work_keys_str_mv | AT sorianojorgel metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT batistanoyde metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT santiestebaneduardo metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT limamayte metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT gonzalezjoaquin metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT garciarobin metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT zarzayohanka metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT lopezmariav metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT rodriguezmyriam metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT loysjorgel metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT montejonarciso metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT aguirrefrank metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT maciasamparo metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer AT vazquezanam metronomiccyclophosphamideandmethotrexatechemotherapycombinedwith1e10antiidiotypevaccineinmetastaticbreastcancer |